Mannkind starts Afrezza pediatric trial

Medicines Afrezza
1

Related news, the MannKind CEO also announced that the Afrezza Pediatric clinical trial has officially started with the first pediatric dose of Afrezza being given within this scope on this past Friday (Sept 29, 2017).

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
NCT02527265
Primary Objective:
-To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM).
Secondary Objectives:
To assess the ability to titrate the prandial and supplemental doses of Afrezza at each meal.
To assess pharmacokinetics (PK) following a prandial dose of Afrezza in children ages 4 to 17 years with T1DM.

6 Likes
2

I wonder if this is something that Lorraine would be interested in… @slee pass the word and we’ll see if we can dig up some more info here

2 Likes
3

I let Lorraine know. I know she is keen.

1 Like